Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
immuno-oncology
Pharma
FDA rejects Hengrui, Elevar PD-1 liver cancer combo a 3rd time
The FDA has declined to approve Hengrui and Elevar’s anti-PD-1/VEGFR combo in first-line liver cancer for a third time.
Angus Liu
Jul 10, 2026 10:55am
BioNTech lays commercial groundwork for PD-L1xVEGF via HER2 ADC
Jul 9, 2026 2:17pm
Nature retracts provocative PD-1 time-of-day study
Jun 24, 2026 11:00am
Another AstraZeneca Emerald glimmers in liver cancer
Apr 2, 2026 10:12am
Editor's Corner—Summit must submit to Big Pharma, stat
Sep 10, 2025 2:50pm
BioNTech works to diversify supply base ahead of oncology launch
May 5, 2025 10:36am
